Curiously, there has been no news from Lilly regarding the US regulatory status of its Locemia nasal glucagon product. Recall, during Lilly’s Q2 ’18 earnings, the company disclosed that it filed the nasal glucagon with FDA in Q2 ’18 (and July in EU). Assuming a 10-month review period, approval was projected by the end of April 2019. Below, FENIX provides thoughts on the Lilly nasal glucagon regulatory situation including the possibility that Lilly received a CRL from FDA.